Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1975 December; 56(6): 1615–1621.
PMCID: PMC333141

Serum calcitonin-lowering effect of magnesium in patients with medullary carcinoma of the thyroid.


The effect of magnesium chloride or magnesium sulfate infusion on circulating levels of immunoreactive calcitonin (iCT) was evaluated on nine occasions in three patients with metastatic medullary carcinoma of the thyroid. One patient was normocalcemic and had normal circulating levels of immunoreactive parathyroid hormone (iPTH), one patient was hypocalcemic and had surgical hypoparathyroidism, and one patient had mild to moderate hypercalcemia associated with bone metastases. The basal serum iPTH levels were undetectable in the latter two patients. In every instance magnesium administration produced a rapid and striking fall in circulating iCT and usually a detectable fall in serum calcium. During the hypermagnesemic state, serum iPTH fell from normal to undetectable in the patient with normal parathyroid function, while serum iPTH levels remained undetectable in the hypoparathyroid patient and in the patient with hypercalcemia associated with bone metastases. The results of these studies indicate that: (a) contrary to what has been reported in normal experimental animals, magnesium administration lowers circulating iCT in human subjects with thyroid medullary carcinoma and (b) the calcium-lowering effect produced by magnesium in patients with medullary carcinoma may, in part at least, be due to a redistribution of body calcium that is not mediated by the actions of either parathyroid hormone or clacitonin.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bell NH. Effects of glucagon, dibutyryl cyclic 3',5'-adenosine monophosphate, and theophylline on calcitonin secretion in vitro. J Clin Invest. 1970 Jul;49(7):1368–1373. [PMC free article] [PubMed]
  • Care AD, Bell NH, Bates RF. The effects of hypermagnesaemia on calcitonin secretion in vivo. J Endocrinol. 1971 Oct;51(2):381–386. [PubMed]
  • Littledike ET, Arnaud CD. The influence of plasma magnesium concentrations on calcitonin secretion in the pig. Proc Soc Exp Biol Med. 1971 Mar;136(3):1000–1006. [PubMed]
  • Conaway HH, Anast CS. Double-antibody radioimmunoassay for parathyroid hormone. J Lab Clin Med. 1974 Jan;83(1):129–138. [PubMed]
  • Deftos LJ. Immunoassay for human calcitonin. I. Method. Metabolism. 1971 Dec;20(12):1122–1128. [PubMed]
  • Deftos LJ, Goodman AD, Engelman K, Potts JT., Jr Suppression and stimulation of calcitonin secretion in medullary thyroid carcinoma. Metabolism. 1971 Apr;20(4):428–431. [PubMed]
  • Melvin KE, Tashjian AH, Jr, Miller HH. Studies in familial (medullary) thyroid carcinoma. Recent Prog Horm Res. 1972;28:399–470. [PubMed]
  • Radde IC, Wittermann ER, Pensuwan S. Effect of thyroid and parathyroid on hypocalcemia occurring after a magnesium load. Endocrinology. 1968 Dec;83(6):1285–1292. [PubMed]
  • Pors Nielsen S. Abolition of magnesium-induced hypocalcaemia by acute thyro-parathyroidectomy in the cat. Acta Endocrinol (Copenh) 1970 May;64(1):150–158. [PubMed]
  • Buckle RM, Care AD, Cooper CW, Gitelman HJ. The influence of plasma magnesium concentration on parathyroid hormone secretion. J Endocrinol. 1968 Dec;42(4):529–534. [PubMed]
  • Pletka P, Bernstein DS, Hampers CL, Merrill JP, Sherwood LM. Effects of magnesium on parathyroid hormone secretion during chronic haemodialysis. Lancet. 1971 Aug 28;2(7722):462–463. [PubMed]
  • Anast CS, Mohs JM, Kaplan SL, Burns TW. Evidence for parathyroid failure in magnesium deficiency. Science. 1972 Aug 18;177(4049):606–608. [PubMed]
  • Suh SM, Tashjian AH, Jr, Matsuo N, Parkinson DK, Fraser D. Pathogenesis of hypocalcemia in primary hypomagnesemia: normal end-organ responsiveness to parathyroid hormone, impaired parathyroid gland function. J Clin Invest. 1973 Jan;52(1):153–160. [PMC free article] [PubMed]
  • Jones KH, Fourman P. Effects of infusions of magnesium and of calcium in parathyroid insufficiency. Clin Sci. 1966 Feb;30(1):139–150. [PubMed]
  • Chakmakjian ZH, Bethune JE. Sodium sulfate treatment of hypercalcemia. N Engl J Med. 1966 Oct 20;275(16):862–869. [PubMed]
  • Fulmer DH, Dimich AB, Rothschild EO, Myers WP. Treatment of hypercalcemia. Comparison of intravenously administered phosphate, sulfate, and hydrocortisone. Arch Intern Med. 1972 Jun;129(6):923–930. [PubMed]
  • Gautvik KM, Tashjian AH., Jr Human medullary thyroid carcinoma: control of calcitonin secretion in vivo and in tissue culture. Horm Metab Res. 1974 Jan;6(1):70–73. [PubMed]
  • Gray TK, Bieberdorf FA, Fordtran JS. Thyrocalcitonin and the jejunal absorption of calcium, water, and electrolytes in normal subjects. J Clin Invest. 1973 Dec;52(12):3084–3088. [PMC free article] [PubMed]
  • A case of diarrhoea and goitre. Demonstrated at The Royal Postgraduate Medical School. Br Med J. 1967 Jul 29;3(5560):293–297. [PMC free article] [PubMed]
  • Ibanez ML, Cole VW, Russell WO, Clark RL. Solid carcinoma of the thyroid gland. Analysis of 53 cases. Cancer. 1967 May;20(5):706–723. [PubMed]
  • Williams ED, Karim SM, Sandler M. Prostaglandin secretion by medullary carcinoma of the thyroid. A possible cause of the associated idarrhoea. Lancet. 1968 Jan 6;1(7532):22–23. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation